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Background:  This study  (NCT00979602)  evaluated  the immunogenicity  and  relative  protective  efﬁcacy
of  one  dose  of inﬂuenza  A(H1N1)pdm09  vaccine  with  or without  AS03  (an  -tocopherol  oil-in-water
emulsion  based  Adjuvant  System).
Methods: Four  thousands  and  forty-eight  healthy  adults  aged  ≥18  years  were  randomized  (1:1)  to
receive  one  dose  of  either  the  adjuvanted  split  virion  (3.75  g hemagglutinin  antigen  [HA]/AS03)  or
non-adjuvanted  (15 g HA)  vaccine.  Hemagglutination  inhibition  [HI]  antibody  response  was  evaluated
before  vaccination  and  at Days  21,  42  and  182  (Month  6). Safety  of the study  vaccines  was  evaluated
during  the entire  study  duration.
Results: At  Day  21, both  study  vaccines  induced  HI immune  responses  meeting  the  US  regulatory  crite-
ria  in subjects  18–64  years  (seroprotection  rate [SPR]:  98.0%  [97.1–98.6];  seroconversion  rate  [SCR]:
89.7%  [88.0–91.2]  in  the  AS03-adjuvanted  group;  SPR:  91.4%  [89.9–92.8];  SCR:  74.6%  [72.3–76.9] in  the
non-adjuvanted  group)  and >64  years  of age  (SPR:  86.0%  [82.5–89.0];  SCR:  75.3%  [71.1–79.2]  in the AS03-
adjuvanted  group;  SPR:  69.1%  [64.6–73.3];  SCR:  56.7%  [52.0–61.3]  in  the  non-adjuvanted  group).  The
AS03-adjuvanted  vaccine  induced  higher  HI geometric  mean  titers  than  the non-adjuvanted  vaccine  at
all  time  points.  At  Month  6, only  subjects  18–64  years  of age from  both  vaccine  groups  still  met  the  US
regulatory  criteria  (SPR:  82.1%  [80.0–84.1];  SCR:  62.3%  [59.6–64.8]  in the  AS03-adjuvanted  group;  SPR:
75.3%  [72.9–77.5];  SCR:  53.7%  [51.0–56.4]  in  the non-adjuvanted  group).  Protective  efﬁcacy  was  not  eval-
uated  due to  low  number  of  RT-qPCR-conﬁrmed  A(H1N1)pdm09  inﬂuenza  cases.  Through  Month  12,  216
serious  adverse  events  (in  157  subjects:  84 in  the  AS03-adjuvanted  and  73  in the non-adjuvanted  group)
and  12  potentially  immune  mediated  diseases  (5 in  the  AS03-adjuvanted  and 7 in  the  non-adjuvanted
group)  were  reported.
Conclusion:  A  single  dose  of either  adjuvanted  or non-adjuvanted  inﬂuenza  A(H1N1)pdm09  vaccine
induced  protective  HI antibody
6  in the  18–64  years  populatio
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. Introduction
Mass immunization is considered to be an effective prophylac-
ic method of mitigating inﬂuenza pandemic-associated morbidity
nd mortality [1–4]. Due to the novel antigenic characteristics of the
wine-origin inﬂuenza A(H1N1) 2009 pandemic virus [inﬂuenza
A(H1N1)pdm09] [5,6], the seasonal inﬂuenza vaccines available at
he time of the 2009–2010 H1N1 pandemic were unlikely to confer
rotection against the novel virus [5,7,8].
The World Health Organization (WHO) encouraged the devel-
pment and use of adjuvanted inﬂuenza A(H1N1)pdm09 vaccines
9,10], with the aim of dose-reduction, antigen-sparing and to
otentially provide broader vaccine efﬁcacy against drifted strains
hrough cross-reactive immunity [11]. Based on the experience
f developing a pre-pandemic A/H5N1 inﬂuenza vaccine utiliz-
ng AS03 (an -tocopherol oil-in-water emulsion based Adjuvant
ystem) [12,13] that was well-tolerated and highly immunogenic
n adults [14–16], an AS03-adjuvanted inﬂuenza A(H1N1)pdm09
accine with 3.75 g hemagglutinin (HA) content was developed
17–19].
This large-scale, randomized study in subjects ≥18 years of
ge assessed whether one dose of AS03-adjuvanted 3.75 g HA
nﬂuenza A(H1N1)pdm09 vaccine elicited immune response that
et  the US and European regulatory criteria. Additionally, non-
nferiority and superiority of this vaccine protective efﬁcacy versus
 non-adjuvanted 15 g HA inﬂuenza A(H1N1)pdm09 vaccine were
valuated.
. Materials and methods
.1.  Study design and participants
In  this phase III, observer-blind, randomized study
NCT00979602), adults ≥18 years of age were enrolled across
5 centers in the US and 13 in Canada between November 2009
nd December 11, 2009. They were randomized (allocation ratio
:1) to receive one dose of either a monovalent AS03-adjuvanted
.75 g HA A/California/7/2009 pandemic inﬂuenza vaccine or a
on-adjuvanted 15 g HA A/California/7/2009 pandemic inﬂuenza
accine. The enrolment stratiﬁcation was by age (1:1:1:1; 18–30
ears, 31–40 years, 41–64 years, ≥65 years). The subjects and
tudy personnel involved in evaluating end points were blinded
o the intervention administered. Double blinding was  not pos-
ible because the vaccine preparation required mixing of AS03
nd A(H1N1)pdm09 antigen from two vials. Randomization was
erformed using a central, internet-based system that balanced
roups with respect to center, age strata and previous seasonal
nﬂuenza vaccination.
Adults  were excluded from enrolment: if they had a history of
hysician-conﬁrmed A(H1N1)pdm09 inﬂuenza infection or vacci-
ation, those who received any vaccination other than a seasonal
nﬂuenza vaccine within 30 days preceding study start, those
ith conﬁrmed or suspected immunosuppressive or immunode-
cient conditions, diagnosed with or undergoing treatment for
ancer, and/or with a history of allergic/anaphylactic reactions
ollowing previous inﬂuenza vaccination. In addition, laboratory
creening was performed to exclude those with results outside
f protocol-speciﬁed normal ranges. The following safety labora-
ory parameters were tested to evaluate the participants’ eligibility:
epatic aminotransferases, total and direct bilirubin, alkaline phos-
hatase, creatinine, serum urea nitrogen, hemoglobin, hematocrit,
hite blood cell count and platelet count.
Active surveillance of inﬂuenza-like infections (ILIs: deﬁned as
ever ≥38.0 ◦C/100.4 ◦F or new or worsening myalgia accompanied
y new or worsening cough or sore throat) was done during study1 (2013) 4389– 4397
visits  and through bi-weekly telephonic contact through Day 385
(12 months after the initially planned administration of the second
study vaccine dose). Additionally, the subjects were instructed to
contact the study sites if they develop any ILI symptoms. Once the
study site had been notiﬁed of a possible ILI episode, a visit for nasal
and throat swab sample collection was  scheduled within 5 days of
symptom onset and before initiating any antimicrobial/inﬂuenza
antiviral therapy. If an ILI episode was  reported more than 5 days
after onset, no swab specimen was  collected.
Written informed consent was obtained from all subjects prior
to conducting any study-related procedures. The study was con-
ducted in accordance with the Good Clinical Practice guidelines,
the Declaration of Helsinki and local regulations. All study-related
documents were approved by institutional review boards.
2.2.  Study vaccines
The  inﬂuenza A(H1N1)pdm09 vaccine was a monovalent,
inactivated, split-virion antigen suspension (A/California/07/2009
strain) adjuvanted with AS03 (ArepanrixTM, a trademark of
GlaxoSmithKline Vaccines) or administered as plain antigen. The
H1N1 viral seed for the vaccine was prepared as per WHO  recom-
mendations [20]. AS03 is an oil-in-water emulsion based Adjuvant
System containing squalene (10.69 mg  per dose), DL--tocopherol
(11.86 mg)  and polysorbate 80 (4.86 mg). The AS03-adjuvanted
inﬂuenza A(H1N1)pdm09 vaccine doses were prepared by mixing
the A(H1N1)pdm09 antigen and AS03 (1:1) from separate multi-
dose vials. 0.5 ml  of the assigned study vaccine was administered
into the deltoid muscle within 30 min  after mixing the antigen and
the adjuvant.
2.3.  Study objectives and end points
The ﬁrst co-primary objective of the study was to evaluate
HI antibody responses 21 days after vaccination in the AS03-
adjuvanted vaccine group based on the Center for Biologics
Evaluation and Research (CBER) and Committee for Medicinal
Products for Human Use (CHMP) criteria for pandemic inﬂuenza
vaccines in adults [21,22].
At  least 360 RT-qPCR-conﬁrmed A/California inﬂuenza cases
were required to evaluate the second co-primary objective on non-
inferior protective efﬁcacy followed by superiority. As only three
RT-qPCR-conﬁrmed A/California inﬂuenza cases were diagnosed
during the study, descriptive analyses of the inﬂuenza attack rate
and vaccine efﬁcacy improvement (VEI) were computed only for ILI
and pneumonia cases.
The  study also assessed whether the non-adjuvanted 15 g HA
inﬂuenza A(H1N1)pdm09 vaccine elicited immune responses that
met  the US and European regulatory criteria, 21 days after vac-
cination and whether these criteria were met for either study
vaccines at Day 42 (in a small subset of subjects) and at Day 182
(Month 6).
2.4.  Laboratory assays
Hemagglutination inhibition (HI) antibody levels in serum sam-
ples were assessed at GlaxoSmithKline Vaccines central laboratory
using a validated in-house assay [cut-off: ≥1:10] that used chicken
erythrocytes, as previously described [23]. The A/California/7/2009
strain was  used as the antigen strain.RT-qPCR was  performed on viral RNA from the clinical samples
as described previously [24]. Viral load values were quantiﬁed and
the sample was  considered positive when the measured viral load
was equal to or above the assay cut-off [24].
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.5. Immunological assessment
Serum  samples were collected before vaccination (Day 0), at
ays 21, 42 (in a subset of subjects) and 182 (Month 6) for assess-
ent of humoral immune response and for clinical chemistry and
ematology assessments at Days 0, 7 and 21.
The immunological assessment was based on HI antibody sero-
onversion rates (SCR), seroprotection rate (SPR) and geometric
ean fold rise (GMFR), against the vaccine homologous strain.
Post  hoc exploratory analyses included the assessment of pos-
ible correlation of HI antibody response with body mass index
BMI) and with previous inﬂuenza vaccination history. Further
ssessments were performed to identify the respiratory viruses iso-
ated from swab samples from ILI cases using xTAG Respiratory
iral Panel (RVP) Fast assay (Luminex Molecular Diagnostics Inc.,
oronto, Canada) [25,26].
.6.  Safety and reactogenicity assessment
Subjects used diary cards to record the solicited local and gen-
ral symptoms occurring within 7 days following vaccination and
he unsolicited adverse events occurring within 42 days following
accination. Potential immune-mediated diseases (pIMDs: subset
f AEs that include both autoimmune diseases and other inﬂam-
atory and/or neurologic disorders which may/may not have an
utoimmune etiology) and serious adverse events (SAEs) were
ecorded throughout the study period. The intensity of all solicited
dverse events except fever was graded on a scale of (0–3), Grade
 being those that did not interfere with normal activities and
rade 3 being those that prevented normal activities (Grade 3 red-
ess and swelling: diameter >100 mm;  Grade 3 fever: temperatures
39.0–≤40.0 ◦C. Fever was graded on a scale of (0–4), Grade 4 being
emperatures >40.0 ◦C. Based on clinical judgment, the investiga-
ors assessed whether the AEs/SAEs were potentially related/not
elated to the study vaccine.
Serum  samples for the analysis of clinical safety laboratory
arameters were collected at Days 7 and 21. The following labora-
ory parameters were tested: hepatic aminotransferases, total and
irect bilirubin, alkaline phosphatase, creatinine, serum urea nitro-
en, hemoglobin, hematocrit, white blood cell count and platelet
ount.
.7. Statistical analyses
The  sample size was calculated taking into consideration the
o-primary objectives. Overall, 1900 evaluable subjects (1800 for
EI evaluation) in each of the two treatment groups (accounting
or 5% and 10% drop-out rates for the co-primary objectives) was
stimated to provide a power of 91.85% to meet the co-primary
bjectives, assuming 90%/74% as reference for SPR/SCR in subjects
8–64 years and >64 years of age, respectively, 40% vaccine efﬁcacy
or the non-adjuvanted inﬂuenza A(H1N1)pdm09 vaccine, and an
ttack rate of 20% in subjects who do not receive any H1N1 vaccine
PASS 2005; one-sided test, one-sided alpha = 2.5%).
The SCR, SPR and GMFR and incidence rates of solicited and
nsolicited adverse events were calculated with 95% conﬁdence
nterval (CI). The analyses of immunogenicity were performed on
he according to protocol (ATP) cohort which included evaluable
ubjects meeting eligibility criteria and adhering to protocol-
eﬁned procedures. A Cox regression model, including the vaccine
roup as a ﬁxed effect, age and baseline antibody titer as covariates
as used to estimate the VEI for the any ILI cases and any pneu-
onia cases (the ﬁrst event was considered if multiple events were
eported by a subject). All statistical analyses were performed using
tatistical Analysis Software (SAS) version 9.1.1 (2013) 4389– 4397 4391
3. Results
3.1. Study population
A  total of 5660 subjects were screened, 4048 received vaccine,
and 3770 completed the study through Day 385. The reasons for
withdrawals and elimination of subjects from the analyses at dif-
ferent time points are presented in Fig. 1.
The mean age of subjects in the TVC at the time of vaccination
in the 18–64 years age group was  37.4 years (range: 18–64 years);
>64 years age group was  71.2 years (range: 65–92 years). Overall,
59.2% and 56.3% of subjects in the respective two age groups were
female and the majority of subjects were Caucasians (86.9% and
93.0%, respectively).
3.2.  Immune response
Co-primary objectives: The ﬁrst co-primary objective was met.
A single dose of the AS03-adjuvanted 3.75 g HA inﬂuenza
A(H1N1)pdm09 vaccine elicited HI immune responses in the 18–64
years and >64 years age groups that met  the CBER regulatory crite-
ria at Day 21 (Table 1). The CHMP criteria were met  in the 18–60
years and >60 years age groups (data not presented).
The second co-primary objective was  not evaluated as only three
RT-qPCR-conﬁrmed A/California inﬂuenza cases were identiﬁed
(AS03-adjuvanted: 1; non-adjuvanted: 2).
Secondary objectives: In the Day 42 subset (N = 192)
which received the AS03-adjuvanted 3.75 g HA inﬂuenza
A(H1N1)pdm09 vaccine, the CBER criteria were met  in the 18–64
years age group and >64 years age group (Table 1). At Day 182
(Month 6), the CBER criteria were met  only for subjects 18–64
years of age (Table 1). Subjects >64 years of age had a LL of the 95%
CI for SPR of 47.7%, thus not fulﬁlling the CBER criteria at this time
point.
At Day 21, a single dose of the non-adjuvanted 15 g HA
inﬂuenza A(H1N1)pdm09 vaccine elicited HI immune responses in
subjects 18–64 years and >64 years of age that met  the CBER reg-
ulatory criteria (Table 1). Only those in the 18–64 years age group
met the CBER criteria at Day 42 and at Day 182 (Month 6). At this
time points subjects >64 years of age had a LLs of the 95% CI for
SPR of 43.2 and 38.6%, respectively and LLs of the 95% CI for SCR of
27.0% and 22.6%, respectively, thus not fulﬁlling the CBER criteria.
The  CHMP criteria were met  at Day 21 and Day 42 in the 18–60
years and >60 years age groups for both study vaccines. At Day
182, the CHMP criteria were met in the 18–60 years age group but
not in the >60 years age group for both study vaccines (data not
presented).
HI antibody GMTs in both age groups were higher at all
post-vaccination time points for those who received the AS03-
adjuvanted inﬂuenza A(H1N1)pdm09 vaccine compared to those
who received the non-adjuvanted vaccine; GMTs were generally
lower in the >64 years compared to the 18–64 years age group at
all time points (Table 1). Persistence of HI antibody response at Day
182 (Month 6) was observed for both study vaccines, although at
lower levels compared to that observed at Day 21 (Table 1). Over-
all, the immune response against the vaccine homologous strain
appeared to decrease with advancing age (Fig. 2/Web-appendix
Table 1).
Post  hoc exploratory analyses showed that HI antibody
responses were mostly comparable across healthy weight, over-
weight and obese subjects. No clear patterns emerged due to
the modest number of subjects in the underweight category
(Web-appendix Table 2). A higher HI antibody was observed among
inﬂuenza vaccine-naïve subjects, compared with those with previ-
ous seasonal inﬂuenza vaccination, in terms of HI antibody GMTs
and GMFRs (Web-appendix Table 2).
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Fig. 1. Participant ﬂow diagram.
Table 1
Hemagglutination inhibition antibody response to the A/California/7/2009 (H1N1) strain in the 18–64 years and >64 years age groups at all time points (according to protocol
cohort for immunogenicity).
Immune response Time point AS03A/3.75 g HAa Non-adjuvanted 15 g HA
18–64 years >64 years 18–64 years >64 years
Nc Percentage or value
(95%  CIb)
N Percentage or value
(95%  CI)
N Percentage or value
(95%  CI)
N Percentage or value
(95%  CI)
Seroconversion rate Day  21 1426 89.7% (88.0–91.2) 454 75.3% (71.1–79.2) 1414 74.6% (72.3–76.9) 455 56.7% (52.0–61.3)
Day  42 52 98.1% (89.7–100) 48 70.8% (55.9–83.0) 46 78.3% (63.6–89.1) 46 41.3% (27.0–56.8)
Day  182 (Month 6) 1383 62.3% (59.6–64.8) 458 34.9% (30.6–39.5) 1380 53.7% (51.0–56.4) 458 26.6% (22.6–30.9)
Seroprotection  rate Pre-vaccination 1428 24.5% (22.3–26.8) 454 13.4% (10.4–16.9) 1420 24.4% (22.2–26.7) 456 17.1% (13.8–20.9)
Day  21 1432 98.0% (97.1–98.6) 457 86.0% (82.5–89.0) 1424 91.4% (89.9–92.8) 456 69.1% (64.6–73.3)
Day  42 52 98.1% (89.7–100) 48 75.0% (60.4–86.4) 46 93.5% (82.1–98.6) 46 58.7% (43.2–73.0)
Day  182 (Month 6) 1388 82.1% (80.0–84.1) 461 51.4% (46.7–56.1) 1391 75.3% (72.9–77.5) 459 43.1% (38.6–47.8)
Geometric  mean titer Pre-vaccination 1428 14.7 (13.8–15.7) 454 10.9 (10.0–11.9) 1420 14.7 (13.7–15.7) 456 12.0 (11.0–13.2)
Day  21 1432 396.2 (373.8–419.9) 457 128.6 (114.6–144.3) 1424 217.6 (203.3–232.9) 456 75.2 (65.9–85.9)
Day  42 52 276.5 (207.1–369.0) 48 105.9 (70.2–159.9) 46 170.0 (117.7–245.4) 46 47.2 (32.1–69.3)
Day  182 (Month 6) 1388 109.5 (102.3–117.1) 461 37.1 (33.2–41.5) 1391 83.3 (77.5–89.5) 459 29.2 (26.0–33.0)
Geometric  mean fold
rise
Day  21 1345 27.7 (25.7–29.9) 535 12.5 (11.2–13.9) 1338 15.5 (14.2–16.8) 531 6.4 (5.7–7.1)
Day  42 50 26.8 (20.0–35.8) 50 11.1 (7.7–16.0) 44 13.7 (9.1–20.6) 1304 5.9 (5.4–6.4)
Day  182 (Month 6) 1302 7.7 (7.2–8.4) 539 3.5 (3.2–3.9) 48 4.0 (2.9–5.5) 534 2.5 (2.3–2.8)
Bolded value = did not meet CBER criteria; SCR: percentage of subjects with pre-vaccination titer <1:10 and post-vaccination titer ≥1:40, or pre-vaccination titer >1:10 and
at  least four-fold increase in post-vaccination titer, SPR: percentage of subjects with a post-vaccination titer ≥1:40; GMFR: post-vaccination fold increase in geometric mean
titers  (GMTs) in terms of HI antibodies against the vaccine homologous strain; Center for Biologics Evaluation and Research (CBER) criteria in adults <65 years of age: lower
bound  of 95% conﬁdence interval [CI] for HI antibody SCR: ≥40% and SPR: ≥70%; CBER criteria in adults ≥65 years of age: lower bound of 95% CI for HI antibody for SCR:
≥30% and SPR: ≥60%; Committee for Medicinal Products for Human Use (CHMP) criteria in adults 18–60 years of age: point estimates for HI antibody SCR: >40%, SPR: >70%
GMFR:  >2.5 [data not presented]; CHMP criteria in adults >60 years of age: point estimates for HI antibody SCR: >30%, SPR: >60% GMFR: >2 [data not presented].
a HA = hemagglutinin.
b CI = conﬁdence interval.
c N = number of subjects with available results.
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Fig. 2. Geometric mean titers for inﬂuenza A(H1N1)pdm09 hemagglutination inhibition antibodies by age strata at Days 21 (A) and 182 (Month 6) (B) (according to protocol
cohort for immunogenicity). Footnotes: HI, hemagglutination inhibition; GMTs, geometric mean titers; ATP, according to protocol.
Table 2
Attack rate and vaccine efﬁcacy increase for ILI cases and vaccine efﬁcacy increase for pneumonia cases occurring during the post study starts periods, Day 0–Day 385 (Month
12)  and Day 14–Day 385 (Month 12) (according to protocol cohort for efﬁcacy).
ARa VEIb
Day 0–Day 385 (Month 12)
Event type Group N n % (95% CIe) % (95% CI)
ILIc AS03A/3.75 g HAd 1950 171 8.77 (7.55–10.11) 11.44 (−8.85–27.95)
Non-adjuvanted 15 g HA 1954 191 9.77 (8.49–11.18) –
Pneumonia AS03A/3.75 g HA 1950 8 0.41 (0.18–0.81) 62.52 (15.19–83.44)
Non-adjuvanted 15 g HA 1954 21 1.07 (0.67–1.64) –
Day  14–Day 385 (Month 12)
Event type Group N n % (95% CI) % (95% CI)
ILI AS03A/3.75 g HA 1950  164 8.41 (7.22–9.73) 7.41 (−14.54–25.15)
Non-adjuvanted 15 g HA 1954 176 9.01 (7.77–10.36) –
Pneumonia AS03A/3.75 g HA 1950 8 0.41 (0.18–0.81) 58.69 (5.35–81.97)
Non-adjuvanted 15 g HA 1954 19 0.97 (0.59–1.51) –
N = number of subjects in each group without missing values; n = number of subjects reporting at least one event in each group; attack rate = percentage of subjects reporting
at  least one ILI case; VEI = relative risk of ILI and pneumonia cases in subjects who received the AS03-adjuvanted 3.75 g HA inﬂuenza A(H1N1)pdm09 vaccine versus subjects
who  received the non-adjuvanted 15 g HA inﬂuenza A(H1N1)pdm09 vaccine.
a AR = attack rate.
b VEI = vaccine efﬁcacy increase.
c ILI = inﬂuenza-like infection.
a
1
a
[
g
O
A
r
t
[
t
w
[
m
t
g
g
gd HA = hemagglutinin.
e CI = conﬁdence interval.
Relative efﬁcacy outcomes: The attack rates and VEIs for ILI cases
nd VEI for pneumonia cases Day 0–Day 385 (Month 12) and Day
4–Day 385 (Month 12) are presented in Table 2. For the efﬁcacy
nalysis of ILIs, 429 ILI cases (195 cases [10.01%] and 234 cases
11.95%] in the AS03-adjuvanted and non-adjuvanted treatment
roups) were reported and 337 were sampled during the study.
f these, 290 samples were tested and only three cases (0.7%) of
(H1N1)pdm09 were conﬁrmed by RT-qPCR (one and two cases
espectively). The incidence of ILI cases was comparable between
he two treatment groups, except through Day 28 (10 versus 18
Day 0–Day 14] and 10 versus 23 [Day 14–Day 28] ILI cases in
he respective treatment groups). Twenty-nine pneumonia cases
ere reported during the entire study period: 8 [0.41%] and 21
1.07%] cases in the AS03-adjuvanted and non-adjuvanted treat-
ent groups, respectively. Of these, 2 cases were diagnosed duringhe ﬁrst 14 days post-vaccination in the non-adjuvanted vaccine
roup, 1 between Days 14 and 28 in the non-adjuvanted vaccine
roup, and 26 between Days 28 and 365 (8 in the AS03-adjuvanted
roup and 18 in the non-adjuvanted group). The VEI was  100% fromDay 0 to Day 28, 62.52% (95% CI: 15.19–83.44) from Day 0 to Day  385
(Month 12) and 58.69% (95% CI: 5.35–81.97) from Day 14 through
Day 385 (Month 12).
Respiratory  viruses: Rhinovirus, identiﬁed from 74 (25.5%)
nasopharyngeal swabs, was the most frequently determined respi-
ratory virus (Table 3).
3.3.  Safety and reactogenicity
Solicited  adverse events: Pain at the injection site was  the
most frequently reported solicited local adverse event. It was
reported for 82.1% and 29.9% of subjects in the 18–64 years age
group who received the AS03-adjuvanted and the non-adjuvanted
inﬂuenza A(H1N1)pdm09 vaccine, respectively (p < 0.0001) and for
56.7% and 9.4% of subjects in the >64 years group who received
the adjuvanted and the non-adjuvanted inﬂuenza A(H1N1)pdm09
vaccine, respectively (p < 0.0001) (Fig. 3/Web-appendix Table 3).
Additionally, in both age groups, a statistically signiﬁcant higher
percentage of subjects receiving the adjuvanted vaccine reported
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sFig. 3. The incidence of solicited local (A) and general (B) adverse event
edness and swelling compared with non-adjuvanted vaccine
roup (p < 0.05 for both). Muscle ache (AS03-adjuvanted/non-
djuvanted:  18–64 years: 39.2%/18.4%, p < 0.0001; >64 years:
9.4%/7.3%, p < 0.0001), fatigue (AS03-adjuvanted/non-adjuvanted:
8–64  years: 30.9%/23.6%, p < 0.0001; >64 years: 17.5%/12.3%,
 = 0.03) and headache (AS03-adjuvanted/non-adjuvanted: 18–64
ears: 29.6%/27.5%, p = 0.21; >64 years: 15.2%/11.5%, p = 0.11) were
he most frequently reported solicited general adverse events
Fig. 3/Web-appendix Table 3). In the 18–64 years age group, a
igher percentage on subjects receiving the adjuvanted vaccine
eported joint pain, shivering and sweating compared with non-
djuvanted group (p < 0.05 for all). In the >64 years group joint
ain was reported by a higher percentage of subjects receiving
djuvanted vaccine compared with the subjects receiving the non-
djuvanted vaccine (p = 0.005). In this age group, no statistically
igniﬁcant differences were observed between vaccine groups inrted during the 7-day post-vaccination period (total vaccinated cohort).
terms of shivering, sweating and fever (p > 0.05). Solicited local and
general adverse events of Grade 3 intensity were reported for ≤3.6%
of subjects. In the 18–64 years age group, the incidence of pain at
the injection site, joint pain and muscle aches of Grade 3 intensity
was signiﬁcantly higher in the adjuvanted vaccine group compared
with the non-adjuvanted group (p < 0.0001 for pain at the injection
site; p = 0.03 for joint pain; p = 0.006 for muscle aches). The inci-
dence of other solicited symptoms of Grade 3 intensity in this age
group, as well as in the >64 years age group, was not statistically sig-
niﬁcant different between the adjuvanted and the non-adjuvanted
vaccine groups (p > 0.05). Reporting of solicited adverse events was
higher in the 18–64 years age group.Unsolicited adverse events: A total of 181 subjects (4.5%;
AS03-adjuvanted: 18–64 years: 87 [5.6%], >64 years: 14 [2.9%];
non-adjuvanted: 18–64 years: 65 [4.2%], >64 years: 15 [3.1%])
reported at least one unsolicited adverse event causally related
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Table  3
Distribution of other respiratory viruses identiﬁed on swab samples collected during
ILIs (total vaccinated cohort).
na %
Number of samples tested 290  100.0
No virus detected 162 55.9
One virus detected Rhinovirus 74 25.5
Human  metapneumovirus
(hMPV)
14  4.8
Human  Coronavirus HKU1 13 4.5
Respiratory  syncytial virus
(RSV)
5  1.7
Human  Coronavirus 229E 5 1.7
Human  Coronavirus OC43 4 1.4
Parainﬂuenzavirus 3 3 1.0
Parainﬂuenzavirus 4 3 1.0
Parainﬂuenzavirus 1 3 1.0
Adenovirus  2 0.7
Inﬂuenza  B 1 0.3
Bocavirus  1 0.3
Two viruses detected Parainﬂuenzavirus 1 0.3
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a n = number of subjects/samples in a given category.
o vaccination, during the 42-day post-vaccination follow-up
eriod.
Overall, 216 SAEs were reported in 157 subjects (3.9%) through
ay 385 (Month 12) (Web appendix Table 4); 84 subjects in the
S03-adjuvanted treatment group, 18–64 years: 2.9%, >64 years:
.1%, and 73 subjects in the non-adjuvanted treatment group,
8–64 years: 2.1%, >64 years: 8.5%. Two of these events, intestinal
bstruction (AS03-adjuvanted treatment group) and multiple scle-
osis (non-adjuvanted treatment group) were considered by the
nvestigator to be possibly related to study vaccine and were also
onsidered pIMDs. Through Day 385 (Month 12), 12 pIMDs accord-
ng to the predeﬁned list of pIMD preferred terms were reported,
ith 5 and 7 in AS03-adjuvanted and non-adjuvanted inﬂuenza
reatment groups, respectively. Seven fatal SAEs were reported, 6
nd 1 in AS03-adjuvanted and non-adjuvanted treatment groups,
espectively. All were assessed by investigators as not related to
accination. A detailed description of all fatal SAEs is provided in
eb  appendix Table 5. Overall, 32 samples had laboratory values
or the hematological and biochemical parameters outside the nor-
al  laboratory reference range at Days 7 and 21. Of these, 14 were
rom subjects in the adjuvanted vaccine group and 18 were from
ubjects in the non-adjuvanted vaccine group.
. Discussion
Data from this large, controlled study in adults 18 years of age
nd older demonstrated that a single dose of AS03-adjuvanted or
on-adjuvanted inﬂuenza A(H1N1)pdm09 vaccine elicited strong
I immune responses 21 days later that met  the CHMP and the
ore stringent CBER criteria for pandemic inﬂuenza vaccines. The
I antibody response persisted through six months after vaccina-
ion for both vaccines, although the CBER criteria were met  only in
he 18–64 years age group and CHMP criteria in the 18–60 years
ge group.
The co-primary objective concerning relative vaccine efﬁcacy
gainst inﬂuenza was not evaluated due to the small number of RT-
PCR-conﬁrmed H1N1/09 inﬂuenza cases. The low number of cases
bserved may  be partially due to the timing of the study; the start
f study vaccination followed the peak of A(H1N1)pdm09 virus
ransmission in the US and Canada by a week or more (last week
f October, 2009), by which time A(H1N1)pdm09 circulation had
iminished considerably. Published estimates of AS03-adjuvanted
nﬂuenza A(H1N1)pdm09 vaccine effectiveness against inﬂuenza
ange from 62.0% to 100.0% [27–30].1 (2013) 4389– 4397 4395
Overall,  the incidence of ILI cases was comparable between the
two groups, except in the ﬁrst 28 days after vaccination (20 versus
41 ILI cases in the AS03-adjuvanted and non-adjuvanted treatment
groups, respectively). This study was not sufﬁciently powered to
detect statistical signiﬁcance in this analysis.
The data for elderly subjects from the present study are in agree-
ment with observations made in previous studies that one dose of
the AS03-adjuvanted 3.75 g HA inﬂuenza A(H1N1)pdm09 vaccine
may be insufﬁcient to meet CBER criteria at 6 months in elderly [31]
and two doses of vaccine administered 21 days apart induce long-
term persistence of HI antibodies at putatively protective levels
[32–34]. Nicholson et al. demonstrated that two  doses of a differ-
ent AS03-adjuvanted inﬂuenza A(H1N1)pdm09 vaccine elicited HI
immune responses that persisted at seroprotective levels in >70%
of subjects ≥65 years of age, up to six months after vaccination,
although at lower levels compared to younger adults (p < 0.0001)
[34].
Similar to other observations [11,17,18,35–40], our results
showed that previous seasonal vaccination appeared to negatively
inﬂuence the strength of the immune response elicited by the
inﬂuenza A(H1N1)pdm09 vaccines, especially in terms of long-
term immunogenicity. There are conﬂicting reports on whether
previous seasonal inﬂuenza vaccination increases the risk of sub-
sequently contracting A(H1N1)pdm09 infection requiring medical
attention [30,41]. The effect of BMI  on immune response was also
studied. Consistent with previous trials [42,43], in the present
study, high BMI  did not appear to impair HI antibody response
shortly after vaccination. However, Sheridan et al. reported a
decrease in HI antibody titers in obese subjects 12 months after
vaccination [43], an observation also made in the present study.
The  reactogenicity and safety proﬁle was  in agreement with
available data in adults and children [19,32,44]. The frequency
of solicited local adverse events in this study was higher in
the AS03-adjuvanted versus the non-adjuvanted treatment group
and the frequency of solicited adverse events were compara-
tively lower in the >64 years age group. Previous clinical trials
of inﬂuenza A(H1N1/)pdm09 vaccines [17,45,2,46] comparing
safety outcomes between adjuvanted and non-adjuvanted vaccines
reported similar observations, with higher frequency of both local
and general adverse events with adjuvanted vaccines compared
with non-adjuvanted vaccines. In our study, we  did not observe
any differences between the two vaccine groups in terms of SAEs
considered as possibly related to vaccination (1 in each group).
Although an imbalance in the number of fatal SAEs was  observed
between the adjuvanted and non-adjuvanted group (6 versus 1),
none were considered to be related to vaccination and they all
occurred in subjects with a relevant medical history.
A  gradual decrement in the HI antibody GMTs elicited by both
study vaccines against the A(H1N1)pdm09 vaccine strain in older
subjects was observed and this could be attributed to “immunose-
nescence” [47,48]. A decreasing trend with advancing age was  also
observed in the frequency of solicited adverse events.
A  possible limitation of this study was the absence of blood sam-
ples collection for assessment of the immune response after Day
182 (Month 6). This period of six months was anticipated to cover
the period of transmission of inﬂuenza virus during one season.
A recently published study enrolling 240 subjects randomized to
receive one or two  doses of the same adjuvanted vaccine and fol-
lowed up to 12 months, showed that regulatory criteria were met
6 months after the administration of the last vaccine dose in sub-
jects aged 18–60 years receiving either one or two vaccine doses
and in subjects aged >60 years receiving two vaccine doses [49]. At
Day 385 (Month 12) the regulatory criteria were still met only in
subjects aged 18–60 years who  received two  vaccine doses.
In  conclusion, a single dose of either adjuvanted or non-
adjuvanted inﬂuenza A(H1N1)pdm09 vaccines elicited protective
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emands for the large number of vaccine doses required to mitigate
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